- PackSize
- 50ug/100ug
- Target
- Transforming growth factor beta-1 proprotein
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Human
- Isotype
- IgG4-kappa
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- Transforming growth factor beta-1 proprotein, Latency-associated peptide, LAP, Transforming growth factor beta-1, TGF-beta-1, TGFB1, Transforming growth factor beta-2 proprotein, Cetermin, Glioblastoma-derived T-cell suppressor factor, G-TSF, Latency-associated peptide, LAP, Transforming growth factor beta-2, TGF-beta-2, TGFB2, Transforming growth factor beta-3 proprotein, Latency-associated peptide, LAP, Transforming growth factor beta-3, TGF-beta-3, TGFB3
- Species
- --
- Gene ID-1
- P01137, P61812, P10600
- Uniprot
- --
- Background
- Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease.<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --